Anavex Life Sciences Corp

(NASDAQ:AVXL)

Latest On Anavex Life Sciences Corp (AVXL):

Date/Time Type Description Signal Details
2023-05-09 09:59 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.01N/A
2023-05-09 09:59 ESTNewsAnavex Life Sciences Corp. (AVXL) Q2 2023 Earnings Call TranscriptN/A
2023-05-08 21:26 ESTNewsAnavex Life Sciences Q2 2023 Earnings PreviewN/A
2023-05-04 09:38 ESTNewsAnavex And The Antioxidant Treatment Of Alzheimer's DiseaseN/A
2023-04-06 10:52 ESTNewsBiogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of RevisionsN/A
2023-03-31 01:41 ESTNewsAnavex gains on long-term data for Parkinson’s disease therapyN/A
2023-03-16 14:51 ESTNewsBuy Anavex For Its Likely Positive Alzheimer's Disease DataN/A
2023-03-08 22:50 ESTNewsAnavex: Many Questions Answered, A Few Still Left, But Things Are Progressing WellN/A
2023-02-09 22:02 ESTNewsAnavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDAN/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.02N/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call TranscriptN/A
2023-02-07 16:43 ESTNewsAnavex hits two-month high after Q1 FY23 resultsN/A
2023-02-06 15:12 ESTNewsAnavex Life Sciences Q1 2023 Earnings PreviewN/A
2023-02-02 15:43 ESTNewsAnavex gains as trial for Rett syndrome candidate exceeds enrollment targetN/A
2023-01-31 00:23 ESTNewsApproval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedN/A
2023-01-17 17:52 ESTNewsAnavex: Drug Treatments For Early Alzheimer's DiseaseN/A
2023-01-12 19:56 ESTNewsAnavex: Despite Positive Spin, No Clarity On AnomaliesN/A
2023-01-06 22:58 ESTNewsLilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approvalN/A
2022-12-21 18:35 ESTNewsHow Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?N/A
2022-12-10 07:25 ESTNewsAnavex: A Thorough Approach To The DataN/A
2022-12-08 04:30 ESTNewsAnavex Life Sciences stock slides as downgraded to neutral at Cantor FitzgeraldN/A
2022-12-06 15:57 ESTNewsAnavex Life Sciences: The Little Company That DidN/A
2022-12-04 07:23 ESTNewsAnavex's Alzheimer's Results Leave Much To Be DesiredN/A
2022-12-02 19:33 ESTNewsAnavex surges 40% as drug improves cognitive function in Alzheimer's patients, meets trial's goalsN/A
2022-12-02 19:32 ESTNewsJones sees Anavex as 'clear M&A target' after Alzheimer's drug's trial successN/A
2022-11-30 14:05 ESTNewsAnavex Life Sciences: Market Unimpressed As Major Alzheimer's Data Readout ArrivesN/A
2022-11-29 21:24 ESTNewsAnavex defended at Cantor on prospects for rare disease therapyN/A
2022-11-29 02:23 ESTNewsAnavex Life Sciences Corp. (AVXL) Q4 2022 Earnings Call TranscriptN/A
2022-11-29 02:23 ESTNewsAnavex drops 16% after fiscal 2022 updateN/A
2022-11-28 08:22 ESTNewsAnavex Life Sciences GAAP EPS of -$0.18 misses by $0.01N/A
2022-11-08 08:37 ESTNewsAnavex Life Sciences At A Pivotal MomentN/A
2022-11-07 15:31 ESTNewsAnavex therapy for Fragile X syndrome gets FDA orphan drug statusN/A
2022-09-29 23:01 ESTNewsBiogen, Eisai cool off after massive run-up following lecanemab Alzheimer's dataN/A
2022-09-21 22:13 ESTNewsAnavex wins new U.S. patent for lead candidateN/A
2022-09-19 19:30 ESTNewsAnavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease DementiaN/A
2022-09-08 07:56 ESTNewsAnavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's DiseaseN/A
2022-08-11 23:27 ESTNewsAnavex And The Debunking Of The Amyloid HypothesisN/A
2022-08-10 12:59 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2022 Results - Earnings Call TranscriptN/A
2022-08-09 19:18 ESTNewsAnavex Life Sciences GAAP EPS of -$0.16 beats by $0.01N/A
2022-08-08 20:39 ESTNewsAnavex Life Sciences Q3 2022 Earnings PreviewN/A
2022-08-01 22:33 ESTNewsAnavex gains on the effect of Alzheimer’s drug on genesN/A
2022-06-24 04:00 ESTNewsAnavex gains as Berenberg launches coverage with Buy ratingN/A
2022-06-02 22:17 ESTNewsAnavex's Blarcamesine: Why It May Treat Alzheimer's DiseaseN/A
2022-05-31 18:54 ESTNewsAnavex: Increasing Shareholder Value Against All OddsN/A
2022-05-11 00:41 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.03N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.05N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-10 02:36 ESTNewsAnavex Life Sciences Q2 2022 Earnings PreviewN/A
2022-03-24 04:50 ESTNewsAnavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's DiseaseN/A
2022-03-15 17:38 ESTNewsAnavex posts mid-stage biomarker data for lead candidateN/A

About Anavex Life Sciences Corp (AVXL):

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

AVXL Quotes by TradingView

See Advanced Chart

General

  • Name Anavex Life Sciences Corp
  • Symbol AVXL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 20
  • Last Split Factor1:4
  • Last Split Date2015-10-07
  • Fiscal Year EndSeptember
  • IPO Date2006-08-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anavex.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 23.64
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.50
  • Next Year EPS Estimate -$0.55
  • Next Quarter EPS Estimate -$0.11
  • Return on Assets -41%
  • Return on Equity -76%
  • Earnings Per Share -$0.60
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.03 billion
  • Analyst Target Price $15.2
  • Book Value Per Share $0.69
View More

Share Statistics

  • Shares Outstanding 69.49 million
  • Shares Float 67.14 million
  • % Held by Insiders 363%
  • % Held by Institutions 19.19%
  • Shares Short 3.96 million
  • Shares Short Prior Month 4.01 million
  • Short Ratio 0.47
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 0.63
  • 52 Week High $16.39
  • 52 Week Low $2.23
  • 50 Day Moving Average 12.26
  • 200 Day Moving Average 6.92
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Anavex Life Sciences Corp (AVXL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Anavex Life Sciences Corp (AVXL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.12-$0.120%
2020-09-302020-12-28$N/A-$0.10-$0.1323.08%
2020-06-302020-08-06$N/A-$0.11-$0.1418.52%
2020-03-312020-05-07$N/A-$0.12-$0.1623.42%
2019-12-312020-02-06$N/A-$0.12-$0.120%
2019-09-302019-12-16$N/A-$0.07-$0.1552.4%
2019-06-302019-08-07$N/A-$0.14-$0.1715.71%
2019-03-312019-05-08$N/A-$0.17-$0.14-21.43%
2018-12-312019-02-07$N/A-$0.16-$0.13-23.08%
2018-09-302018-12-12$N/A-$0.13-$0.11-18.18%
2018-06-302018-08-09$N/A-$0.06-$0.1041.92%
2018-03-312018-05-10$N/A-$0.11-$0.10-10%
2017-12-312018-02-07$N/A-$0.09
2017-09-302017-12-11$N/A-$0.12-$0.10-20%
2017-06-302017-08-07$N/A-$0.09-$0.091.33%
2017-03-312017-05-10$N/A-$0.04-$0.0955.56%
2016-12-312017-02-07$N/A-$0.08-$0.1127.27%
2016-09-302016-12-12$N/A-$0.18
2016-06-302016-08-11$N/A-$0.06-$0.0924.59%
2016-03-312016-05-11$N/A-$0.06-$0.1660.81%
2015-12-312016-02-08$N/A-$0.12-$0.1414.29%
2015-09-302015-12-29$N/A-$0.21-$0.06-250%
2015-06-302015-08-17$N/A-$0.22
2015-03-312015-05-15$N/A-$0.12
2014-12-312015-02-18$N/A-$0.06
2014-09-302014-12-29$N/A-$0.20-$0.200%
2014-06-302014-08-13$N/A-$0.10
2014-03-312014-05-28$N/A-$0.11
2013-12-312014-02-26$N/A$0.03
2013-09-302013-09-30$N/A-$0.40
2013-06-302013-06-30$N/A-$0.02
2013-03-312013-03-31$N/A-$0.01
2012-12-312012-12-31$N/A-$0.06
2012-09-302012-09-30$N/A-$0.10
2012-06-302012-06-30$N/A-$0.64
2012-03-312012-03-31$N/A-$0.13
2011-12-312011-12-31$N/A-$0.33
2011-09-302011-09-30-$0.23
2011-06-302011-06-30$N/A-$0.25
2011-03-312011-03-31-$0.31
2010-12-312010-12-31-$0.31
2010-09-302010-09-30-$0.52
2010-06-302010-06-30-$0.37
2010-03-312010-03-31-$0.33
2009-12-312009-12-31-$0.09
2009-09-302009-09-30-$0.36
2009-06-302009-06-30-$0.27
2009-03-312009-03-31-$0.25
2008-12-312008-12-31-$0.19
2008-09-302008-09-30-$0.42
2008-06-302008-06-30-$0.34
2008-03-312008-03-31-$0.14
2007-12-312007-12-31-$0.19
2007-09-302007-09-30-$0.24
2007-06-302007-06-30-$0.05
2007-03-312007-03-31-$0.04
2006-12-312006-12-31$-0.00
2006-09-302006-09-30$-0.00

Anavex Life Sciences Corp (AVXL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Anavex Life Sciences Corp (AVXL) Chart:

Anavex Life Sciences Corp (AVXL) News:

Below you will find a list of latest news for Anavex Life Sciences Corp (AVXL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Anavex Life Sciences Corp (AVXL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-1710CALL0 10TRUE00
2026-07-1720.7CALL5 296.81TRUE0.70
2026-07-1730.17CALL167 48489.5FALSE00
2026-07-1740.05CALL3 823121.12FALSE0.050
2026-07-1750CALL0 686127.08FALSE00
2026-07-1760CALL0 1280277.7FALSE00
2026-07-1770.1CALL1 796177.39FALSE0.10
2026-07-1780CALL0 5577222.14FALSE00
2026-07-17100CALL0 474226.27FALSE00
2026-07-1710PUT0 0583.43FALSE00
2026-07-1720.08PUT40 236264.16FALSE0.080
2026-07-1730.56PUT11 732102.05TRUE0.560
2026-07-1741.42PUT4 31150.05TRUE1.420
2026-07-1750PUT0 40110.72TRUE00
2026-07-1760PUT0 0169.96TRUE00
2026-07-1770PUT0 0194.67TRUE00
2026-07-1780PUT0 0215.5TRUE00
2026-07-17100PUT0 00TRUE00
2026-08-2110CALL0 0264.85TRUE00
2026-08-2120CALL0 0280.59TRUE00
2026-08-2130CALL0 0301.35FALSE00
2026-08-2140CALL0 0103.43FALSE00
2026-08-2150CALL0 0354.21FALSE00
2026-08-2160CALL0 0374.09FALSE00
2026-08-2110PUT0 00FALSE00
2026-08-2120PUT0 0434.67FALSE00
2026-08-2130PUT0 0275.38TRUE00
2026-08-2140PUT0 0196.91TRUE00
2026-08-2150PUT0 0143.08TRUE00
2026-08-2160PUT0 0142.81TRUE00
2026-10-1610CALL0 10TRUE00
2026-10-1620CALL0 197.21TRUE00
2026-10-1630.43CALL5 53102.94FALSE0.430
2026-10-1640CALL0 34106.19FALSE00
2026-10-1650CALL0 29092.27FALSE00
2026-10-1660CALL0 8158.36FALSE00
2026-10-1670CALL0 4181.75FALSE00
2026-10-1680CALL0 151161.52FALSE00
2026-10-1690CALL0 2348.44FALSE00
2026-10-1610PUT0 0288.9FALSE00
2026-10-1620.26PUT0 141109.3FALSE00
2026-10-1630PUT0 9117.11TRUE00
2026-10-1640PUT0 22109.34TRUE00
2026-10-1652.38PUT3 1131.22TRUE2.380
2026-10-1660PUT0 1120.97TRUE00
2026-10-1670PUT0 0135.9TRUE00
2026-10-1680PUT0 5118.29TRUE00
2026-10-1690PUT0 0145.95TRUE00
2027-01-1510CALL0 4515.07TRUE00
2027-01-1520CALL0 3130.88TRUE00
2027-01-1530.75CALL0 98198.12FALSE00
2027-01-1540CALL0 3585.44FALSE00
2027-01-1550.3CALL8 108280.82FALSE-0.1-0.25
2027-01-1560CALL0 42118.7FALSE00
2027-01-1570.25CALL0 1374136.37FALSE00
2027-01-15100.15CALL0 6194112.82FALSE00
2027-01-15120CALL0 1815128.26FALSE00
2027-01-15150CALL0 1770134.98FALSE00
2027-01-15170CALL0 353181.16FALSE00
2027-01-15200.11CALL0 2791136.16FALSE00
2027-01-15220CALL0 349216.09FALSE00
2027-01-15250CALL0 487166.38FALSE00
2027-01-15270CALL0 173157.73FALSE00
2027-01-1510PUT0 0294.11FALSE00
2027-01-1520PUT0 65232.67FALSE00
2027-01-1531PUT0 434105.92TRUE00
2027-01-1540PUT0 40109.83TRUE00
2027-01-1550PUT0 235109.09TRUE00
2027-01-1560PUT0 0111.16TRUE00
2027-01-1570PUT0 95205.53TRUE00
2027-01-15100PUT0 97150.85TRUE00
2027-01-15120PUT0 18235.86TRUE00
2027-01-15150PUT0 0140.53TRUE00
2027-01-15170PUT0 0173.32TRUE00
2027-01-15200PUT0 0209.9TRUE00
2027-01-15220PUT0 0192.29TRUE00
2027-01-15250PUT0 0177.84TRUE00
2027-01-15270PUT0 0183.5TRUE00
2028-01-2131.1CALL1 56890.11FALSE-0.17-0.13
2028-01-2150CALL0 247206.49FALSE00
2028-01-2170.8CALL0 80166.98FALSE00
2028-01-21100CALL0 379253.1FALSE00
2028-01-21120CALL0 158319.9FALSE00
2028-01-21150CALL0 2326.34FALSE00
2028-01-21170CALL0 84139.07FALSE00
2028-01-2130PUT0 30552.99TRUE00
2028-01-2150PUT0 2150TRUE00
2028-01-2170PUT0 2920TRUE00
2028-01-21100PUT0 270TRUE00
2028-01-21120PUT0 20113.96TRUE00
2028-01-21150PUT0 36126.34TRUE00
2028-01-21170PUT0 2133.46TRUE00

Latest AVXL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$7.57
Jun 13, 2022 7:59 PM EST58$7.56
Jun 13, 2022 7:59 PM EST1$7.57
Jun 13, 2022 7:59 PM EST100$7.57
Jun 13, 2022 7:59 PM EST29$7.56

Anavex Life Sciences Corp (AVXL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2017-06-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000017020197/0000000000-17-020197-index.htm
2019-07-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000019011025/0000000000-19-011025-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720008231/0000834237-20-008231-index.htm
2020-03-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720009195/0000834237-20-009195-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571818000242/0000905718-18-000242-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571819000231/0000905718-19-000231-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571820000234/0000905718-20-000234-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010249/0001213900-19-010249-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/0001213900-19-010601-index.htm
2019-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019010604/0001213900-19-010604-index.htm
2019-07-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019012072/0001213900-19-012072-index.htm
2019-07-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000121390019012578/0001213900-19-012578-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019014791/0001213900-19-014791-index.htm
2019-09-13S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019018007/0001213900-19-018007-index.htm
2019-09-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019018012/0001213900-19-018012-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018023/0001213900-19-018023-index.htm
2019-09-16AWAmendment Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018132/0001213900-19-018132-index.htm
2019-09-17POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018310/0001213900-19-018310-index.htm
2017-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000161577417003075/0001615774-17-003075-index.htm
2017-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004118/0001615774-17-004118-index.htm
2017-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004290/0001615774-17-004290-index.htm
2017-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004964/0001615774-17-004964-index.htm
2017-09-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005634/0001615774-17-005634-index.htm
2017-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2017-12-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/0001615774-17-007272-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007355/0001615774-17-007355-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007357/0001615774-17-007357-index.htm
2018-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418000934/0001615774-18-000934-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001673/0001615774-18-001673-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001701/0001615774-18-001701-index.htm
2018-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm
2018-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002786/0001615774-18-002786-index.htm
2018-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002846/0001615774-18-002846-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418003574/0001615774-18-003574-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004019/0001615774-18-004019-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004023/0001615774-18-004023-index.htm
2018-07-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418006278/0001615774-18-006278-index.htm
2018-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/0001615774-18-006280-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418007805/0001615774-18-007805-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010436/0001615774-18-010436-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010439/0001615774-18-010439-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010441/0001615774-18-010441-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010443/0001615774-18-010443-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010445/0001615774-18-010445-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010447/0001615774-18-010447-index.htm
2018-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010620/0001615774-18-010620-index.htm
2018-12-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
2019-01-2510-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577419001031/0001615774-19-001031-index.htm
2019-01-31PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419001498/0001615774-19-001498-index.htm
2019-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419002057/0001615774-19-002057-index.htm
2019-02-11DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/0001615774-19-002242-index.htm
2019-03-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419004136/0001615774-19-004136-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419004139/0001615774-19-004139-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/0001615774-19-005452-index.htm
2019-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419007213/0001615774-19-007213-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/0001615774-19-007324-index.htm
2019-12-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000173112219000784/0001731122-19-000784-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000018/0001731122-20-000018-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000019/0001731122-20-000019-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000020/0001731122-20-000020-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000021/0001731122-20-000021-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000022/0001731122-20-000022-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000023/0001731122-20-000023-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000024/0001731122-20-000024-index.htm
2020-02-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/0001731122-20-000103-index.htm
2020-02-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000195/0001731122-20-000195-index.htm
2020-03-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000289/0001731122-20-000289-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000360/0001731122-20-000360-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000430/0001731122-20-000430-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000431/0001731122-20-000431-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/0001731122-20-000432-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000447/0001731122-20-000447-index.htm
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000711/0001731122-20-000711-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000807/0001731122-20-000807-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001047/0001731122-20-001047-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001114/0001731122-20-001114-index.htm
2017-06-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999517001508/9999999995-17-001508-index.htm
2019-07-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519001606/9999999995-19-001606-index.htm
2019-09-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519002138/9999999995-19-002138-index.htm

Anavex Life Sciences Corp (AVXL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anavex Life Sciences Corp (AVXL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 363%
Institutional Ownership: 1919%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-08-11CHRISTOPHER U MISSLINGPresident and CEOBuy750.003.552,662.501,004,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.701,387.501,004,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.811,428.751,004,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-21CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.071,526.251,005,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.541,702.501,005,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.441,665.001,005,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-31CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.481,680.001,006,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.901,837.501,006,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.761,785.001,007,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-11CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.811,803.751,007,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.581,717.501,007,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.401,650.001,008,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-20CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.231,586.251,008,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-26CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.881,455.001,008,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.211,578.751,009,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-02CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.201,575.001,009,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.301,612.501,010,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-13CHRISTOPHER U MISSLINGPresident and CEOBuy750.004.223,165.001,010,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-17CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.271,601.251,011,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-19CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.491,683.751,011,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.921,845.001,011,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-25CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.391,646.251,012,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2018-03-02CHRISTOPHER U MISSLINGDirector, President & CEOBuy1,650.002.413,976.501,013,900.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-05CHRISTOPHER U MISSLINGPresident and CEOBuy1,500.002.633,945.001,015,400.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-06CHRISTOPHER U MISSLINGPresident and CEOBuy1,450.002.733,958.501,016,850.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-07CHRISTOPHER U MISSLINGPresident and CEOBuy1,360.002.923,971.201,018,210.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm